Aryx Therapeutics Working Capital

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

Aryx Therapeutics I fundamentals help investors to digest information that contributes to Aryx Therapeutics' financial success or failures. It also enables traders to predict the movement of Aryx Therapeutics Pink Sheet. The fundamental analysis module provides a way to measure Aryx Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aryx Therapeutics pink sheet.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Aryx Therapeutics Working Capital Analysis

Aryx Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Working Capital 
 = 
Current Assets 
Current Liabilities 
More About Working Capital | All Equity Analysis

Current Aryx Therapeutics Working Capital

    
  126 K  
Most of Aryx Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aryx Therapeutics I is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Compare to competition

In accordance with the company's disclosures, Aryx Therapeutics I has a Working Capital of 126 K. This is 99.97% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 99.99% higher than that of the company.

Aryx Therapeutics Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.
Aryx Therapeutics is currently under evaluation in working capital category among related companies.

Aryx Therapeutics Fundamentals

About Aryx Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aryx Therapeutics I's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics I based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aryx Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aryx Therapeutics' short interest history, or implied volatility extrapolated from Aryx Therapeutics options trading.

Pair Trading with Aryx Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aryx Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aryx Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Aryx Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aryx Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aryx Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aryx Therapeutics I to buy it.
The correlation of Aryx Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aryx Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aryx Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aryx Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Aryx Therapeutics Piotroski F Score and Aryx Therapeutics Altman Z Score analysis. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.